Diagnostic microRNAs in myelodysplastic syndrome

Experimental Hematology

Volumn 39, Issue 9, 2011, Pages

  Erdogan, Begum ^a   Facey, Crystal ^b   Qualtieri, Julianne ^a   Tedesco, Jason ^a   Rinker, Elizabeth ^a   Isett, R Benjamin ^c   Tobias, John ^c   Baldwin, Donald A ^c   Thompson, James E ^c,d   Carroll, Martin ^c   Kim, Annette S ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Anesthesiology   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; ONCOPROTEIN; PARAFFIN; PROTEIN C MYB; PROTEIN SUFU; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CELL ISOLATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; EMBEDDING; FEMALE; FROZEN SECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 80051475292     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.06.002     Document Type: Article

References (43)

1. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
2. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC Press, Lyon, France. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
3. Garzon R., Croce C.M. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008, 15:352-358.
4. Ebert B.L., Pretz J., Bosco J., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
5. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010, 16:49-58.
6. Hussein K., Theophile K., Busche G., et al. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res 2010, 34:328-334.
7. Barroga C.F., Pham H., Kaushansky K. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol 2008, 36:1585-1592.
8. Hussein K., Theophile K., Busche G., et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010, 34:1169-1174.
9. Pons A., Nomdedeu B., Navarro A., et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009, 50:1854-1859.
10. Sokol L., Caceres G., Volinia S., et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011, 153:24-32.
11. Nelson P.T., Baldwin D.A., Scearce L.M., Oberholtzer J.C., Tobias J.W., Mourelatos Z. Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods 2004, 1:155-161.
12. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
13. Bruchova H., Yoon D., Agarwal A.M., Mendell J., Prchal J.T. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 2007, 35:1657-1667.
14. Haferlach T., Kohlmann A., Wieczorek L., et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010, 28:2529-2537.
15. Mills K.I., Kohlmann A., Williams P.M., et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 2009, 114:1063-1072.
16. Eichner L.J., Perry M.C., Dufour C.R., et al. miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab 2010, 12:352-361.
17. Feng M., Li Z., Aau M., Wong C.H., Yang X., Yu Q. Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene 2011, 30:2242-2251.
18. Kahai S., Lee S.C., Lee D.Y., et al. MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PloS One 2009, 4:e7535.
19. Lee D.Y., Deng Z., Wang C.H., Yang B.B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 2007, 104:20350-20355.
20. Mohri T., Nakajima M., Fukami T., Takamiya M., Aoki Y., Yokoi T. Human CYP2E1 is regulated by miR-378. Biochem Pharmacol 2010, 79:1045-1052.
21. Yang G.H., Wang F., Yu J., Wang X.S., Yuan J.Y., Zhang J.W. MicroRNAs are involved in erythroid differentiation control. J Cell Biochem 2009, 107:548-556.
22. Hussein K., Dralle W., Theophile K., Kreipe H., Bock O. Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm. Ann Hematol 2009, 88:325-332.
23. Garzon R., Pichiorri F., Palumbo T., et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A 2006, 103:5078-5083.
24. Fatica A., Rosa A., Ballarino M., De Marchis M.L., Rasmussen K.D., Bozzoni I. Role of microRNAs in myeloid differentiation. Biochem Soc Trans 2008, 36:1201-1205.
25. Merkerova M., Belickova M., Bruchova H. Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol 2008, 81:304-310.
26. Lionetti M., Biasiolo M., Agnelli L., et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009, 114:e20-e26.
27. Nicolas F.E., Pais H., Schwach F., et al. Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140. RNA 2008, 14:2513-2520.
28. Pais H., Nicolas F.E., Soond S.M., et al. Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein level. RNA 2010, 16:489-494.
29. Pizzimenti S., Ferracin M., Sabbioni S., et al. MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radic Biol Med 2009, 46:282-288.
30. Wang S., Olson E.N. AngiomiRs-key regulators of angiogenesis. Curr Opin Genet Dev 2009, 19:205-211.
31. Veronese A., Lupini L., Consiglio J., et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 2010, 70:3140-3149.
32. Sundaram K., Mani S.K., Kitatani K., Wu K., Pestell R.G., Reddy S.V. DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells. J Cell Biochem 2008, 103:1747-1759.
33. Lung J., Liu K.J., Chang J.Y., Leu S.J., Shih N.Y. MBP-1 is efficiently encoded by an alternative transcript of the ENO1 gene but post-translationally regulated by proteasome-dependent protein turnover. FEBS J 2010, 277:4308-4321.
34. Green M., Gandhi M.K., Camilleri E., Marlton P., Lea R., Griffiths L. High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma. Leuk Res 2009, 33:731-734.
35. Pallasch C.P., Patz M., Park Y.J., et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 2009, 114:3255-3264.
36. Patz M., Pallasch C.P., Wendtner C.M. Critical role of microRNAs in chronic lymphocytic leukemia: overexpression of the oncogene PLAG1 by deregulated miRNAs. Leuk Lymphoma 2010, 51:1379-1381.
37. Starkova J., Zamostna B., Mejstrikova E., Krejci R., Drabkin H.A., Trka J. HOX gene expression in phenotypic and genotypic subgroups and low HOXA gene expression as an adverse prognostic factor in pediatric ALL. Pediatr Blood Cancer 2010, 55:1072-1082.
38. Takakuwa T., Luo W.J., Ham M.F., Sakane-Ishikawa F., Wada N., Aozasa K. Integration of Epstein-Barr virus into chromosome 6q15 of Burkitt lymphoma cell line (Raji) induces loss of BACH2 expression. Am J Pathol 2004, 164:967-974.
39. Soza-Ried C., Hess I., Netuschil N., Schorpp M., Boehm T. Essential role of c-myb in definitive hematopoiesis is evolutionarily conserved. Proc Natl Acad Sci U S A 2010, 107:17304-17308.
40. Wheadon H., Ramsey J.M., Dobbin E., et al. Differential Hox expression in murine embryonic stem cell models of normal and malignant hematopoiesis. Stem Cells Dev 2011 Jan 5, [Epub ahead of print].
41. Ramsay R.G., Gonda T.J. MYB function in normal and cancer cells. Nat Rev 2008, 8:523-534.
42. Cheng S.Y., Bishop J.M. Suppressor of fused represses Gli-mediated transcription by recruiting the SAP18-mSin3 corepressor complex. Proc Natl Acad Sci U S A 2002, 99:5442-5447.
43. Paces-Fessy M., Boucher D., Petit E., Paute-Briand S., Blanchet-Tournier M.F. The negative regulator of Gli, Suppressor of fused (Sufu), interacts with SAP18, Galectin3 and other nuclear proteins. Biochem J 2004, 378:353-362.